Decoy Therapeutics (DCOY) Status update summary

Company Overview, Technology, and Strategic Achievements

• Developing designable multi-antivirals (DMAVs) that target multiple viruses with a single drug, using AI and machine learning for rapid molecule design and synthesis, with a proprietary IMPACT platform compressing drug development timelines from years to months.

• Formed strategic AI partnerships with Quantori and Google Cloud to boost peptide design capacity by up to 100x, accelerating candidate discovery and optimization.

• Lead programs include DCOY-COV (pan-coronavirus) and DCOY-TRI (multi-virus for flu, RSV, and COVID), with clinical entry targeted for 2027 and 2028, respectively, and both showing broad in vitro activity.

• Drugs are self-administered via nasal spray or inhaler for both treatment and prophylactic use, with a patented manufacturing process enabling single-step purification and reducing cost and time.

• Supported by non-dilutive funding from Gates Foundation, Google, NVIDIA, BARDA, and the EU, and recognized as a Hello Tomorrow Deep Tech Pioneer.

Market Opportunity and Differentiation

• Addressing large markets: pan-coronavirus program targets a $4.96 billion market; multi-virus program addresses up to 70% of respiratory infections.

• DMAVs target conserved viral fusion cores, reducing risk of resistance and maintaining efficacy across variants, unlike vaccines and antibodies.

• Drugs are affordable to manufacture ($1–$2 per dose), supporting broad access and a volume-based strategy.

• Opportunity to fill gaps left by declining vaccine uptake and limitations of current antivirals like Paxlovid.

• Positioned to benefit from trends in AI-driven drug discovery, pandemic preparedness, and peptide therapeutics.

Clinical and Development Strategy

• Utilizing human challenge studies for rapid clinical proof-of-concept, with timelines from IND to phase IIa in about one year.

• High probability of success in antivirals post-phase IIa (70% approval rate), with relatively low trial costs and patient numbers.

• Multiple upcoming milestones in the next 12–24 months, including lead candidate selection, IND-enabling studies, publications, animal data, PK/tox results, and IND filings.

• Actively seeking strategic, academic, and commercial partnerships to accelerate development, with robust investor relations and social media strategy.

• Plans to provide more detail on clinical and commercial strategy for lead programs.